News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,471 Results
Type
Article (44367)
Company Profile (473)
Press Release (694619)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209405)
Career Advice (2043)
Deals (36160)
Drug Delivery (119)
Drug Development (84126)
Employer Resources (174)
FDA (16697)
Job Trends (15200)
News (354405)
Policy (33309)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2678)
Accelerated approval (36)
Adcomms (28)
Allergies (146)
Alliances (51142)
ALS (179)
Alzheimer's disease (1775)
Antibody-drug conjugate (ADC) (330)
Approvals (16937)
Artificial intelligence (548)
Autoimmune disease (159)
Automation (39)
Bankruptcy (373)
Best Places to Work (11849)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (653)
Cancer (4944)
Cardiovascular disease (418)
Career advice (1727)
Career pathing (38)
CAR-T (294)
CDC (46)
Celiac Disease (2)
Cell therapy (785)
Cervical cancer (36)
Clinical research (71552)
Collaboration (1807)
Company closure (4)
Compensation (1185)
Complete response letters (65)
COVID-19 (2774)
CRISPR (98)
C-suite (886)
Cystic fibrosis (152)
Data (6328)
Decentralized trials (2)
Denatured (39)
Depression (143)
Diabetes (507)
Diagnostics (6761)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (271)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (245)
Earnings (91466)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121076)
Executive appointments (1008)
FDA (19857)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1540)
Gene editing (214)
Generative AI (45)
Gene therapy (650)
GLP-1 (1015)
Government (4765)
Grass and pollen (6)
Guidances (384)
Healthcare (19224)
HIV (60)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (275)
Immuno-oncology (62)
Indications (111)
Infectious disease (3049)
Inflammatory bowel disease (198)
Inflation Reduction Act (17)
Influenza (119)
Intellectual property (254)
Interviews (316)
IPO (16936)
IRA (53)
Job creations (3716)
Job search strategy (1443)
JPM (66)
Kidney cancer (16)
Labor market (85)
Layoffs (581)
Leadership (33)
Legal (8026)
Liver cancer (93)
Longevity (14)
Lung cancer (666)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (813)
MASH (171)
Medical device (13935)
Medtech (13988)
Mergers & acquisitions (20302)
Metabolic disorders (1324)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (349)
Neuropsychiatric disorders (98)
Neuroscience (3076)
Neurotech (1)
NextGen: Class of 2026 (6782)
Non-profit (4594)
Now hiring (67)
Obesity (633)
Opinion (282)
Ovarian cancer (168)
Pain (205)
Pancreatic cancer (233)
Parkinson's disease (296)
Partnered (34)
Patents (500)
Patient recruitment (505)
Peanut (57)
People (60349)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22491)
Phase 2 (31546)
Phase 3 (23318)
Pipeline (5351)
Policy (298)
Postmarket research (2613)
Preclinical (9627)
Press Release (67)
Prostate cancer (246)
Psychedelics (56)
Radiopharmaceuticals (298)
Rare diseases (896)
Real estate (6067)
Recruiting (71)
Regulatory (25042)
Reports (52)
Research institute (2501)
Resumes & cover letters (355)
Rett syndrome (27)
RNA editing (21)
RSV (77)
Schizophrenia (156)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (104)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3809)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (82)
Vaccines (1035)
Venture capital (95)
Weight loss (411)
Women's health (93)
Worklife (19)
Date
Today (22)
Last 7 days (615)
Last 30 days (2077)
Last 365 days (30686)
2026 (3556)
2025 (31087)
2024 (36309)
2023 (41036)
2022 (52313)
2021 (56794)
2020 (54951)
2019 (47471)
2018 (35732)
2017 (33072)
2016 (32428)
2015 (38466)
2014 (32283)
2013 (27219)
2012 (29322)
2011 (29939)
2010 (28074)
Location
Africa (755)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40792)
Australia (6793)
California (11517)
Canada (3315)
China (1145)
Colorado (487)
Connecticut (497)
Delaware (339)
Europe (89482)
Florida (1701)
Georgia (359)
Hawaii (3)
Idaho (61)
Illinois (886)
India (66)
Indiana (525)
Iowa (24)
Japan (438)
Kansas (130)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1407)
Massachusetts (8374)
Michigan (327)
Minnesota (641)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3065)
New Mexico (31)
New York (3018)
North Carolina (1535)
North Dakota (9)
Northern California (5604)
Ohio (338)
Oklahoma (21)
Oregon (45)
Pennsylvania (2307)
Puerto Rico (24)
Rhode Island (49)
South America (1124)
South Carolina (66)
South Dakota (1)
Southern California (4466)
Tennessee (175)
Texas (1771)
United States (40964)
Utah (340)
Vermont (1)
Virginia (268)
Washington D.C. (82)
Washington State (956)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
739,471 Results for "cognition therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
February 5, 2026
·
7 min read
Press Releases
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
January 28, 2026
·
6 min read
Press Releases
Feinstein Institutes’ Research Pinpoints Core Cause of Vascular Cognitive Impairment, Unlocking New Therapeutic Avenues for Cognitive Decline
December 8, 2025
·
3 min read
Press Releases
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
November 21, 2025
·
4 min read
Press Releases
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
January 6, 2026
·
8 min read
Press Releases
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
November 14, 2025
·
9 min read
Press Releases
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
December 3, 2025
·
7 min read
Press Releases
Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares
October 1, 2025
·
5 min read
Press Releases
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
November 14, 2025
·
8 min read
Press Releases
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
November 7, 2025
·
8 min read
1 of 73,948
Next
